PTK2 and hepatocellular carcinoma: In summary, these findings demonstrate that sorafenib activates FAK signaling, which promotes cholesterol biosynthesis, leading to activation of the SHH pathway effector GLI1 and ultimately inducing sorafenib resistance in HCC cells.